343 related articles for article (PubMed ID: 16798839)
21. Regression of systemic lupus erythematosus after development of an acquired toll-like receptor signaling defect and antibody deficiency.
Visentini M; Conti V; Cagliuso M; Tinti F; Siciliano G; Trombetta AC; Mitterhofer AP; Fiorilli M; Quinti I
Arthritis Rheum; 2009 Sep; 60(9):2767-71. PubMed ID: 19714644
[TBL] [Abstract][Full Text] [Related]
22. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population.
Tao K; Fujii M; Tsukumo S; Maekawa Y; Kishihara K; Kimoto Y; Horiuchi T; Hisaeda H; Akira S; Kagami S; Yasutomo K
Ann Rheum Dis; 2007 Jul; 66(7):905-9. PubMed ID: 17344245
[TBL] [Abstract][Full Text] [Related]
23. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.
Barrat FJ; Meeker T; Chan JH; Guiducci C; Coffman RL
Eur J Immunol; 2007 Dec; 37(12):3582-6. PubMed ID: 18034431
[TBL] [Abstract][Full Text] [Related]
24. Antibodies to DNA: infection or genetics?
Pisetsky DS; Vrabie IA
Lupus; 2009 Nov; 18(13):1176-80. PubMed ID: 19880564
[TBL] [Abstract][Full Text] [Related]
25. [B-cell anomalies in systemic lupus erythematosus].
Tron F; Jacquot S; Gilbert D
Ann Med Interne (Paris); 2002 Dec; 153(8):503-12. PubMed ID: 12610424
[TBL] [Abstract][Full Text] [Related]
26. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
27. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus.
Means TK; Luster AD
Ann N Y Acad Sci; 2005 Dec; 1062():242-51. PubMed ID: 16461805
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes.
Boulé MW; Broughton C; Mackay F; Akira S; Marshak-Rothstein A; Rifkin IR
J Exp Med; 2004 Jun; 199(12):1631-40. PubMed ID: 15197227
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients.
Capolunghi F; Rosado MM; Cascioli S; Girolami E; Bordasco S; Vivarelli M; Ruggiero B; Cortis E; Insalaco A; Fantò N; Gallo G; Nucera E; Loiarro M; Sette C; De Santis R; Carsetti R; Ruggiero V
Rheumatology (Oxford); 2010 Dec; 49(12):2281-9. PubMed ID: 20739362
[TBL] [Abstract][Full Text] [Related]
30. The role of positive feedback loops involving anti-dsDNA and anti-anti-dsDNA antibodies in autoimmune glomerulonephritis.
Arazi A; Neumann AU
J Theor Biol; 2013 Feb; 319():8-22. PubMed ID: 23142592
[TBL] [Abstract][Full Text] [Related]
31. Distinct autoantibody profiles in systemic lupus erythematosus patients are selectively associated with TLR7 and TLR9 upregulation.
Chauhan SK; Singh VV; Rai R; Rai M; Rai G
J Clin Immunol; 2013 Jul; 33(5):954-64. PubMed ID: 23564191
[TBL] [Abstract][Full Text] [Related]
32. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.
Summers SA; Hoi A; Steinmetz OM; O'Sullivan KM; Ooi JD; Odobasic D; Akira S; Kitching AR; Holdsworth SR
J Autoimmun; 2010 Dec; 35(4):291-8. PubMed ID: 20810248
[TBL] [Abstract][Full Text] [Related]
33. A genetic locus controlling aging-sensitive regression of B lymphopoiesis in an autoimmune-prone MRL/lpr strain of mice.
Nakatani K; Qu WM; Zhang MC; Fujii H; Furukawa H; Miyazaki T; Iwano M; Saito Y; Nose M; Ono M
Scand J Immunol; 2007 Dec; 66(6):654-61. PubMed ID: 17983422
[TBL] [Abstract][Full Text] [Related]
34. Toll-like receptor engagement stimulates anti-snRNP autoreactive B cells for activation.
Ding C; Wang L; Al-Ghawi H; Marroquin J; Mamula M; Yan J
Eur J Immunol; 2006 Aug; 36(8):2013-24. PubMed ID: 16810634
[TBL] [Abstract][Full Text] [Related]
35. Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells.
Halcomb KE; Musuka S; Gutierrez T; Wright HL; Satterthwaite AB
Mol Immunol; 2008 Dec; 46(2):233-41. PubMed ID: 18849077
[TBL] [Abstract][Full Text] [Related]
36. Fate of immune complexes, glomerulonephritis, and cell-mediated vasculitis in lupus-prone MRL/Mp lpr/lpr mice.
Cruse JM; Lewis RE; Dilioglou S
Exp Mol Pathol; 2000 Dec; 69(3):211-22. PubMed ID: 11115362
[TBL] [Abstract][Full Text] [Related]
37. TLR9 and the recognition of self and non-self nucleic acids.
Lamphier MS; Sirois CM; Verma A; Golenbock DT; Latz E
Ann N Y Acad Sci; 2006 Oct; 1082():31-43. PubMed ID: 17145922
[TBL] [Abstract][Full Text] [Related]
38. Genetic basis of murine lupus.
Santiago-Raber ML; Laporte C; Reininger L; Izui S
Autoimmun Rev; 2004 Jan; 3(1):33-9. PubMed ID: 14871647
[TBL] [Abstract][Full Text] [Related]
39. TLR9 as a key receptor for the recognition of DNA.
Kumagai Y; Takeuchi O; Akira S
Adv Drug Deliv Rev; 2008 Apr; 60(7):795-804. PubMed ID: 18262306
[TBL] [Abstract][Full Text] [Related]
40. Features of systemic lupus erythematosus in Dnase1-deficient mice.
Napirei M; Karsunky H; Zevnik B; Stephan H; Mannherz HG; Möröy T
Nat Genet; 2000 Jun; 25(2):177-81. PubMed ID: 10835632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
